Show simple item record

dc.contributor.authorMartínez-Vélez, Nen_US
dc.contributor.authorGarcia-Moure, Men_US
dc.contributor.authorMarigil, Men_US
dc.contributor.authorGonzález-Huarriz, Men_US
dc.contributor.authorPuigdelloses, Men_US
dc.contributor.authorGallego Pérez-Larraya, Jen_US
dc.contributor.authorZalacaín, Men_US
dc.contributor.authorMarrodán, Len_US
dc.contributor.authorVarela-Guruceaga, Men_US
dc.contributor.authorLaspidea, Ven_US
dc.contributor.authorAristu, JJen_US
dc.contributor.authorRamos, LIen_US
dc.contributor.authorTejada-Solís, Sen_US
dc.contributor.authorDíez-Valle, Ren_US
dc.contributor.authorJones, Cen_US
dc.contributor.authorMackay, Aen_US
dc.contributor.authorMartínez-Climent, JAen_US
dc.contributor.authorGarcía-Barchino, MJen_US
dc.contributor.authorRaabe, Een_US
dc.contributor.authorMonje, Men_US
dc.contributor.authorBecher, OJen_US
dc.contributor.authorJunier, MPen_US
dc.contributor.authorEl-Habr, EAen_US
dc.contributor.authorChneiweiss, Hen_US
dc.contributor.authorAldave, Gen_US
dc.contributor.authorJiang, Hen_US
dc.contributor.authorFueyo, Jen_US
dc.contributor.authorPatiño-García, Aen_US
dc.contributor.authorGomez-Manzano, Cen_US
dc.contributor.authorAlonso, MMen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-06-07T10:44:06Z
dc.date.issued2019-05-28en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/31138805en_US
dc.identifier10.1038/s41467-019-10043-0en_US
dc.identifier.citationNat Commun, 2019, 10 (1), pp. 2235 - ?en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3257
dc.identifier.eissn2041-1723en_US
dc.identifier.doi10.1038/s41467-019-10043-0en_US
dc.description.abstractPediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).en_US
dc.format.extent2235 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectAdenoviridaeen_US
dc.subjectAnimalsen_US
dc.subjectBrain Neoplasmsen_US
dc.subjectBrain Stem Neoplasmsen_US
dc.subjectCell Line, Tumoren_US
dc.subjectCell Survivalen_US
dc.subjectComputer Simulationen_US
dc.subjectDisease Models, Animalen_US
dc.subjectGliomaen_US
dc.subjectHumansen_US
dc.subjectIn Vitro Techniquesen_US
dc.subjectMiceen_US
dc.subjectNeoplasm Gradingen_US
dc.subjectOncolytic Virotherapyen_US
dc.subjectOncolytic Virusesen_US
dc.subjectXenograft Model Antitumor Assaysen_US
dc.titleThe oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.en_US
dc.typeJournal Article
dcterms.dateAccepted2019-04-16en_US
rioxxterms.versionofrecord10.1038/s41467-019-10043-0en_US
rioxxterms.licenseref.startdate2019-05-28en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfNat Communen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.publication-statusPublished onlineen_US
pubs.volume10en_US
pubs.embargo.termsNot knownen_US
icr.researchteamGlioma Teamen_US
dc.contributor.icrauthorJones, Chrisen_US
dc.contributor.icrauthorMackay, Alanen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/